Skip to main content

Peer Review reports

From: Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial

Original Submission
23 Dec 2015 Submitted Original manuscript
21 Jun 2016 Author responded Author comments - Perparim Limani
Resubmission - Version 2
21 Jun 2016 Submitted Manuscript version 2
15 Jul 2016 Author responded Author comments - Perparim Limani
Resubmission - Version 3
15 Jul 2016 Submitted Manuscript version 3
27 Jul 2016 Author responded Author comments - Perparim Limani
Resubmission - Version 4
27 Jul 2016 Submitted Manuscript version 4
30 Aug 2016 Author responded Author comments - Perparim Limani
Resubmission - Version 5
30 Aug 2016 Submitted Manuscript version 5
Publishing
12 Oct 2016 Editorially accepted
19 Oct 2016 Article published 10.1186/s12885-016-2855-3

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us